All In Biotech

Drug Trial Radar · NCT05531890

Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects

Crossover Study to Evaluate the Comparative Bioavailability, Pharmacokinetics, and Safety of GTX-102 Administered as an Oral Spray Compared to Intramuscular Injection and an Oral Solution of Betamethasone in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jan 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

48

Actual

Start

Sep 13, 2022

Primary completion

Nov 24, 2022

Study completion May 3, 2023

Sponsor

Lead sponsor
Grace Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Sep 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Randomized, Open-label, Crossover Study to Evaluate the Comparative Bioavailability, Pharmacokinetics, and Safety of GTX-102 Administered as an Oral Spray Compared to Intramuscular Injection - betamethasone and an Oral Solution of Betamethasone in Healthy Subjects. Four groups of subjects will receive 2 treatments each and randomized in 2-way crossover.

Conditions

  • Ataxia Telangiectasia

Interventions

  • GTX-102 medium dose fast Period 1 and Period 2Drug

    GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 fast

  • GTX-102 medium dose slow Period 1 and Period 2Drug

    GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 slow

  • GTX-102 high dose fast Period 1 and Period 2Drug

    GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast

  • GTX-102 low dose fast Period 1 and Period 2Drug

    GTX-102 Betamethasone oral spray high dose (0.025 mg/kg) administered in Period 1 and Period 2 fast

  • Betamethasone solution as intramuscular injection Period 1 and Period 2Drug

    reference product 0.1 mg/kg betamethasone solution as an intramuscular injection

  • Betamethasone Oral Solution Period 1 and Period 2Drug

    Comparator product 0.1 mg/kg betamethasone oral drops solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC from 0 to 72 hours post-doseTime frame: Up to 72 hours post-dose
  2. AUCTime frame: Up to infinity
  3. Cmax from 0 to 72 hours post-doseTime frame: Up to 72 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Unit

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.